

Freedom of Information Request: Our Reference CTMUHB_175_22

You asked:

We are making a Freedom of Information Act (FOI) request of all CCGs, Health Boards and Health and Social Care Trusts to assess the level of osteoporosis treatment in primary care.

Q1. For the financial years 2019/2020, 2020/2021 and 2021/22 how much did you spend on:

Osteoporosis medication with:

i) Oral bisphosphonates (alendronate, risedronate, ibandronate)

ii) Denosumab

	Primary care spend		
	2019-20	2020-21	2021-22 (11 months only)
oral bisphosphonates	£186,235	£135,476	£80,092
denosumab	£90,290	£98,217	£89,348

Please note the following:

- We currently only have data up to Feb 22
- We are unable to determine the indication for which the medication is prescribed so may not be just for osteoporosis.

iii) DXA scans. Please provide:

i) budget/spend for DXA

- 2019/2020
- 2020/2021
- 2021/2022

Info to follow.

ii) Number of scans this provided

- 2019/2020
- 2020/2021
- 2021/2022

Info to follow.

iii) DXA VFA (vertebral fracture assessment) scans commissioned

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Q2. What proportion of GP practices have a systematic process in place (e.g., regular data search) for identifying people who require a fracture risk assessment?

The Health Board do not hold this information. GPs are independent contractors. Therefore, for detailed information relating to GP practices, you will need to contact them directly. To assist you with your request, a list of practices that fall under the CTMUHB is available via the following link: [Health in Wales | GP Surgeries in Cwm Taf Morgannwg University Health Board](#)

Q3. What proportion of GP practices have osteoporosis identification/management tools embedded into their electronic patient management systems?

- a) FRAX
- b) QFracture
- c) Other (please state)

Please see response to question 2.

Q4. For financial years 2019/20, 2020/2021 and 2021/22.

a) What proportion of patients across your Health Board aged 50 and over had a fracture risk assessment using FRAX or QFracture in line with NICE / NOGG recommendations?

- i. 2019/2020
- ii. 2020/2021
- iii. 2021/2022

b) What proportion of these were referred for a DXA scan?

- i. 2019/2020
- ii. 2020/2021
- iii. 2021/2022

Please see response to question 2.

Q5. What proportion of practices have an identified clinician or other healthcare professional with special interest in osteoporosis?

Please see response to question 2.

Q6. How much of your Additional Role Reimbursement Scheme funds have you invested into community pharmacists?

Not applicable in Wales, that we are aware.

Q7. What proportion of GP practices have access to a community pharmacist (CP)?

100% - There are 110 community pharmacies within CTMUHB, all GP practices have access to these community pharmacies and pharmacies outside of CTMUHB for those practices working across Health Board boundaries.

- i. **What proportion of these CPs have a designated role in identifying/managing osteoporosis?**

100% of pharmacies providing NHS contracted services provide essential services and therefore dispense medication and provide advice relating

to the management of osteoporosis to patients as part of the dispensing, signposting and advice for self care elements of the NHS community pharmacy contract. There are no specific NHS commissioned community pharmacy enhanced services relating to the identification and management of osteoporosis, community pharmacy.

ii. What proportion of these CPs routinely perform osteoporosis medication reviews?

The Health Board do not hold this information.

Q8. What proportion of GP practices have access to a First Contact Practitioner (FCP)?

And, what proportion of these FCPs have a designated role in identifying/managing OP?

We do not have FCPs.

Q9. What proportion of patients being treated in primary care with osteoporosis medications have had a review of their medication within 12 months of treatment initiation?

The Health Board do not hold this information.

Q10. What proportion of patients being treated in primary care with oral bisphosphonate therapy have had their treatment reviewed at 5 years of treatment?

The Health Board do not hold this information.